Navigation Links
Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Date:5/25/2011

e Reactions

The most common adverse reactions (greater than or equal to 5%) reported in clinical trials were joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia and upper respiratory tract infection.

Drug Interactions

ZYTIGA™ is an inhibitor of the hepatic drug-metabolizing enzyme CYP2D6.  Avoid co-administration with CYP2D6 substrates that have a narrow therapeutic index.  If an alternative cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.  Additionally, abiraterone is a substrate of CYP3A4 in vitro.  Strong inhibitors and inducers of CYP3A4 should be avoided or used with caution.

About Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer, or CRPC, occurs when cancer has metastasized beyond the prostate and disease progresses despite serum testosterone below castrate levels.  

The prostate is a gland located around the urethra (under the bladder) in men that produces part of the seminal fluid.  In some cases, cancer of the prostate can grow slowly compared with other cancers.  However, depending on factors including characteristics specific to the patient and the tumor, prostate cancer also can grow very quickly and spread widely.

Excluding skin cancer, prostate cancer is the most frequently diagnosed cancer in men in the United States.  In 2010, more than 217,000 new cases of prostate cancer were estimated and more than 32,000 men died from the disease.

About ZYTIGA (abiraterone acetate)

ZYTIGA (abiraterone acetate) was developed by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc., and is marketed by Centocor Ortho Biotech Inc.  Marketing applications for ZYT
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)...  Today, in final recognition of the Centers for ... 1-800 Contacts is sharing how to keep lens cases ... who do not properly care for their lens cases ... Most contact lens wearers understand the importance ... case is sometimes overlooked.  When proper steps to clean ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... The Cleveland Clinic and Valence Health announced today that ... become a clinically integrated network.  This new network, the ... physicians, and more than 1,000 private practitioners in the ... Physician Partnership (CPP), recognized the need to pursue Clinical ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), ... accelerating the development and enhancing the value of oncology ... Chief Financial Officer. Mr. Schonau indicated that he has ... other opportunities. Champions is seeking chief financial officer candidates ...
Cached Medicine Technology:Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program 2Champions' CFO Resigns 2
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... , WASHINGTON, Sept. 18 The ... every VA medical site with endoscopic equipment, independently verifying the ... and sterile procedures for reprocessing endoscopic equipment across the country. ... provide the highest quality care to the Veterans of this ...
... in hospital patients also leads to higher costs, study ... popular stomach acid reducer greatly increases the risk of ... study has found. , Researchers at Wake Forest University ... of 834 cardiothoracic surgery patients on breathing machines who ...
... , WASHINGTON, Sept. 18 In response to the ... Max Baucus, DMLR Chairman Stuart L. Weinstein, M.D. issued the following ... Baucus is inadequate in addressing the serious problems caused by medical ... health care policy experts, opinion leaders, and patients all across the ...
... , , , WEINER,S NEW YORK ... , WASHINGTON, Sept. 18 The Public Option is still ... ,fading, nor ,waning, (New York Times) nor on ,life support, (ABC News)," says ... Health subcommittee, and later spokesman for the White House National Drug Policy Office. ...
... , , IDAHO FALLS, Idaho, ... announces the successful conclusion of a private placement completed among ... International Isotopes Inc. successfully completed a private placement ... $1 million. In this private placement, the Company offered ...
... N.Y., Sept. 18 IPRO has won a new ... research findings aimed at improving the quality and safety ... Agency for Healthcare Research and Quality,s (AHRQ,s) Knowledge Transfer/Implementation ... accelerated dissemination of evidence-based products that improve the quality ...
Cached Medicine News:Health News:Inspector General Completes Study of VA Endoscopic Programs 2Health News:Ulcer Preventative May Raise Pneumonia Risks 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Public Option Still Viable As House Set to Pass It -- Not 'Fading,' Says Robert Weiner, Former House Aging Committee Director 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 3Health News:IPRO Wins Knowledge Transfer/Implementation Federal Contract From AHRQ 2
Large, bright images from a bronchoscope designed for routine examination and treatment....
... The BF-1T40 has been designed with ... versatility in therapeutic applications. This permits the ... including those for electrosurgical procedures. In addition, ... wide field of view and a bright, ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... scope designed specifically to enable direct inspection ... suitable for pediatric applications as well. Its ... mere 2.8mm across. As a result, insertion ... with greater ease. And since this sophisticated ...
Medicine Products: